Lantheus Awarded Premier Agreements For Ultrasound, MRI Contrast Agents

October 26, 2011 – Lantheus Medical Imaging announced it has been awarded three-year supplier contracts with Premier Purchasing Partners, the group purchasing unit of the Premier healthcare alliance, in the category of cardiac ultrasound contrast media for its ultrasound contrast agent, Definity Vial for (perflutren lipid microsphere) Injectable Suspension, and its magnetic resonance angiography (MRA) blood pool imaging agent, Ablavar (gadofosveset trisodium).

The cardiac ultrasound contrast media contract award is a three-year sole-source supplier agreement, effective Dec. 1, 2011 through Nov. 30, 2014. The Ablavar contract award is a three-year supplier agreement, effective Jan. 1, 2012, through Dec. 31, 2014. These new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Definity and Ablavar .

Definity, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border cardiograms, and Ablavar, an MRA contrast agent indicated to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD), will both be offered to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites. The contracts were awarded after a competitive bidding process that examined multiple factors, including pricing and clinical experience with Definity and Ablavar, as well as Lantheus’ support of the products.

For more information: www.lantheus.com, www.ablavar.com


Related Content

News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Radiology Business

July 19, 2024 — GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s ...

Time July 19, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Feature | Women's Health | By Jordan Bazinsky

Investing in women’s health should not merely be a metric on the equity dashboard — it should drive policy and tactical ...

Time July 08, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Clinical Trials

June 27, 2024 — Prenuvo, which makes whole-body MRI screening for early cancer detection and other diseases, has ...

Time June 27, 2024
arrow
Subscribe Now